AzTrials
AzTrials

Fluid ResponsivenessNCT07546656

Prediction of Fluid Responsiveness Using the Femoral Vein-to-Artery Diameter Ratio

An observational study of Fluid Responsiveness and Acute Circulatory Failure, run by Istanbul University - Cerrahpasa at 1 site in Turkey (Türkiye).

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This prospective single-center observational study aims to evaluate whether the ultrasound-measured femoral vein-to-femoral artery diameter ratio can predict fluid responsiveness in mechanically ventilated adult intensive care patients with acute circulatory failure or shock. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Ultrasound Measurement of Femoral Vein-to-Femoral Artery Diameter Ratio
How many people
100 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 May 2026to 1 Mar 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population consists of adult intensive care unit patients with acute circulatory failure or shock who are receiving invasive mechanical ventilation and for whom the responsible intensive care physician has determined a clinical indication for a fluid challenge. Only patients who already have PiCCO monitoring in place as part of routine clinical care and in whom femoral vein and femoral artery ultrasonographic measurements can be obtained will be enrolled.

Who may be able to join

  • Adult patients aged 18 years or older
  • Admission to the intensive care unit where the study is being conducted
  • Receiving invasive mechanical ventilation
  • Clinical indication for a fluid challenge due to acute circulatory failure or shock, as determined by the responsible intensive care physician
  • PiCCO monitoring already in place as part of routine clinical care
  • Clinical conditions allowing collection of pre- and post-fluid challenge cardiac index and ultrasonographic measurements
  • Technical feasibility of femoral vein and femoral artery diameter measurements by ultrasonography

Who cannot join

  • Age younger than 18 years
  • Failure to obtain written informed consent from the patient or legally authorized representative before enrollment
  • Absence of PiCCO monitoring as part of routine clinical care or no clinical plan for fluid challenge
  • Inability to complete pre- and post-fluid challenge measurements (e.g., early death, urgent surgery, transfer)
  • Local conditions preventing reliable femoral ultrasonographic assessment, including open wound, infection, dressing, major anatomic obstacle, poor image quality, known femoral vein thrombosis, or severe vascular pathology on the relevant side
  • Conditions likely to significantly impair the reliability of thermodilution measurements (e.g., severe tricuspid regurgitation or significant intracardiac shunt)
  • Major treatment changes during the fluid challenge that preclude comparable measurements (e.g., major vasopressor dose change, major ventilator setting change, new arrhythmia)
  • Missing or inadequate data judged by the investigators to compromise data integrity, including absence of measurements required for the primary outcome

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Turkey (Türkiye)1 site, 1 recruiting
  • Istanbul University Cerrahpasa Medical Faculty

    Istanbul, Istanbul

    mert katılmış, medical doctor, +905346430560, mertkatilmis97@gmail.com

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: Prediction of Fluid Responsiveness Using the Femoral Vein-to-Artery Diameter Ratio: A Prospective Observational Study

This prospective single-center observational study aims to evaluate whether the ultrasound-measured femoral vein-to-femoral artery diameter ratio can predict fluid responsiveness in mechanically ventilated adult intensive care patients with acute circulatory failure or shock. Only patients who already have PiCCO monitoring as part of routine clinical care and for whom a fluid challenge is clinically indicated will be included. No additional invasive procedure will be performed for study purposes. Cardiac index will be measured with PiCCO before and after administration of 500 mL balanced crystalloid over 10 minutes, and femoral vein and femoral artery diameters will be measured by bedside ultrasonography. Fluid responsiveness will be defined as an increase of more than 10% in cardiac index after fluid administration. The study will assess the diagnostic performance of the femoral vein-to-femoral artery diameter ratio as a practical bedside parameter to support hemodynamic decision-making in critically ill patients.

Read the detailed description

Acute circulatory failure and shock are common conditions in the intensive care unit, and fluid administration remains a key component of hemodynamic management. However, unnecessary fluid loading may worsen tissue edema, oxygenation, and organ function. Therefore, practical bedside tools that help identify fluid-responsive patients are clinically important.

The aim of this study is to evaluate the clinical utility of the ultrasound-measured femoral vein-to-femoral artery diameter ratio in predicting fluid responsiveness in mechanically ventilated adult ICU patients with acute circulatory failure or shock. This is a prospective, single-center, observational study.

No additional invasive intervention will be performed for research purposes. PiCCO monitoring will not be initiated for study reasons; only patients who already have PiCCO monitoring as part of routine ICU management and who are scheduled to undergo a clinically indicated fluid challenge will be enrolled.

Before the fluid challenge, cardiac index will be recorded using PiCCO, and femoral vein and femoral artery diameters will be measured by bedside ultrasonography at the same anatomical level proximal to the femoral artery bifurcation. Each ultrasound measurement will be repeated at least three times, and the mean value will be recorded. A fluid challenge consisting of 500 mL balanced crystalloid administered over 10 minutes will then be performed according to routine clinical care. After the fluid challenge, cardiac index and the femoral vein-to-femoral artery diameter ratio will be reassessed using the same methods.

Fluid responsiveness will be defined as an increase of more than 10% in cardiac index after fluid administration. Responders and non-responders will be compared, and the diagnostic performance of the femoral vein-to-femoral artery diameter ratio will be analyzed.

Demographic data, baseline clinical findings, hemodynamic measurements, and ultrasound measurements will be collected and analyzed. Appropriate descriptive statistics, group comparisons, and diagnostic performance analyses will be used to evaluate the discriminative ability of the femoral vein-to-femoral artery diameter ratio. All data will be de-identified and handled in accordance with patient confidentiality principles.

Being tested
Ultrasound Measurement of Femoral Vein-to-Femoral Artery Diameter Ratio
Keywords
Fluid Responsiveness, Shock, Acute Circulatory Failure, Hemodynamic Monitoring, Ultrasonography, Femoral Vein, Femoral Artery, PiCCO
Medical subject headings
Shock

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasound Measurement of Femoral Vein-to-Femoral Artery Diameter RatioDiagnostic test

    Bedside ultrasonographic measurement of femoral vein and femoral artery diameters at the same anatomical level proximal to the femoral artery bifurcation, with at least three repeated measurements and calculation of the femoral vein-to-femoral artery diameter ratio before and after a clinically indicated fluid challenge.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic performance of the baseline femoral vein-to-femoral artery diameter ratio for predicting fluid responsiveness

    Diagnostic performance of the baseline ultrasound-measured femoral vein-to-femoral artery diameter ratio in identifying fluid responders, assessed by receiver operating characteristic analysis (area under the curve). Fluid responsiveness will be defined as an increase of more than 10% in cardiac index after administration of 500 mL balanced crystalloid over 10 minutes.

    Measured: Baseline assessment before fluid challenge, with responder status determined 10 minutes after completion of the fluid challenge

Secondary outcomes (1)
  1. Percent change in cardiac index after fluid challenge

    Percent change in PiCCO-derived cardiac index after administration of 500 mL balanced crystalloid over 10 minutes.

    Measured: Before fluid challenge and 10 minutes after completion of the fluid challenge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Apr 2026
  2. Study start1 May 2026
  3. Primary completion31 Jan 2027 (estimated)
  4. Study completion1 Mar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07546656
Sponsor's protocol ID
E-24687260-604.01-1615271
Status last verified
May 2026
First submitted
16 Apr 2026
Last updated
11 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Fluid Responsiveness and Acute Circulatory Failure, run by Istanbul University - Cerrahpasa at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact mert katılmış (+905346430560, mertkatilmis97@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic performance of the baseline femoral vein-to-femoral artery diameter ratio for predicting fluid responsiveness (time frame: Baseline assessment before fluid challenge, with responder status determined 10 minutes after completion of the fluid challenge). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in